v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:        
Total revenue $ 1 $ 135 $ 6 $ 151
Cost of revenue 30 30
Gross profit 1 105 6 121
Operating expenses:        
Research and development 1,145 1,733 3,916 4,701
General and administrative 2,815 4,774 18,167 15,477
Depreciation and amortization 92 84 268 210
Total operating expenses 4,052 6,591 22,351 20,388
Loss from operations (4,051) (6,486) (22,345) (20,267)
Other income (expense):        
Interest income, net 1 1 8 1
Other income (expense), net: (225)
Loss before income taxes (4,050) (6,485) (22,562) (20,266)
Income taxes (benefit)
Net loss (4,050) (6,485) (22,562) (20,266)
Non-controlling interest (517) 113 (430) 172
Net loss attributable to BioSig Technologies, Inc. (4,567) (6,372) (22,992) (20,094)
Preferred stock dividend (2) (2) (7) (7)
Preferred stock deemed dividend (17) (125)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (4,569) $ (6,391) $ (22,999) $ (20,226)
Net loss per common share, basic $ (0.06) $ (0.14) $ (0.33) $ (0.50)
Net loss per common share, diluted $ (0.06) $ (0.14) $ (0.33) $ (0.50)
Weighted average number of common shares outstanding, basic 75,372,373 45,015,574 69,077,898 40,311,669
Weighted average number of common shares outstanding, diluted 75,372,373 45,015,574 69,077,898 40,311,669
Product [Member]        
Revenue:        
Total revenue $ 127 $ 127
Service [Member]        
Revenue:        
Total revenue $ 1 $ 8 $ 6 $ 24

Source